SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Epoch Pharmaceuticals Inc. EPPH

No earlier versions found for this Subject.


Return to Epoch Pharmaceuticals Inc. EPPH
 
Anybody following this stock. I have posted the yahoo Profile below

Epoch Pharmaceuticals Inc. is a biomedical company utilizing nucleoside and nucleotide chemistry to develop molecular tools for genetic analysis. Utilizing unique and proprietary technology in the rational design, synthesis and chemical modification of oligonucleotides, the Company has positioned itself to provide products and techniques for high throughput genetic sequence analysis that are in increasing demand in the rapidly expanding field of genetic pharmacology. Previously, Epoch's therapeutic research and development program had focused on the modification of gene expression by altering cellular genomic DNA using oligonucleotide targeting technology combined with chemical reactivity. Epoch's technology is based on its expertise in designing and synthesizing oligonucleotides bearing modifications that selectively bind to and interact with the target genes.
Financial Summary
Epoch Pharmaceuticals is a biomedical company utilizing nucleoside and nucleotide chemistry to develop molecular tools for genetic analysis, providing products and techniques for high throughput genetic sequence anaylsis. For the nine months ended 9/99, revenues rose 35% to $170 thousand. Net loss from continuing operations fell 17% to $3.4 million. Results reflect increased R&D contract revenue, offset by increased interest expense caused by a $3 million note payable.
Officers
F. Craves Ph.D., Chmn.
S. Zwiefach, Pres./CFO/Secy.
W. Gerber, CEO
R. Meyer Ph.D., VP
R. Wydro Ph.D., VP.